Bulk Pharmaceutical API Sources for furazolidone

Bulk Pharmaceutical API Sources for furazolidone

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		F9505_SIGMA
Biosynth		F-8900
NovoSeek		3435
NovoSeek		5323714
Vitas-M Laboratory		STK388219

Bulk Active Pharmaceutical Ingredient (API) Sources for Furazolidone

Last updated: February 20, 2026

Furazolidone is a nitrofuran derivative used primarily as an antimicrobial agent in veterinary medicine and, historically, in human medicine. Its API sourcing involves a mix of domestic manufacturers and international suppliers, mainly from China and India, which dominate global API production.

Leading API Manufacturers for Furazolidone

Manufacturer	Location	Certification	Production Capacity	Notes
Zhejiang Hailian Biotech	China	GMP, ISO 9001	50 kg/month	One of the major Chinese producers
Jiangsu Guoxin Pharmaceutical	China	GMP, ISO 9001	30 kg/month	Supplies to Asia and Europe
Aurobindo Pharma	India	GMP	20 kg/month	Distributes globally
Hetero Labs	India	GMP	15 kg/month	Supplies mainly to Asia

Note: Volumes are approximate and vary with demand and regulatory approvals.

Sources and Supply Chain Dynamics

• China: Accounts for over 80% of global API production for furazolidone. The country's API industry has mature manufacturing infrastructure, large-scale chemical complexes, and export networks. Chinese companies often supply both active ingredients and intermediates directly to pharmaceutical companies.

• India: Supplies a smaller portion, focusing on a cost-effective manufacturing process. Indian API producers generally comply with GMP standards, enabling exports to regulated markets.

• Regional Suppliers: Limited number of companies in Europe and North America manufacture furazolidone APIs, often for niche or local markets. European producers tend to meet stricter regulatory standards, with fewer suppliers available.

Regulatory Considerations

• Global Regulations: Furazolidone is banned or restricted in many countries due to safety concerns, impacting supply chains. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have classified furazolidone as unsuitable for human use. Usage persists in veterinary medicine in some regions with regulatory exceptions.

• GMP Compliance: Suppliers with GMP certification are preferred for APIs destined for markets with stringent regulatory requirements. Many Chinese and Indian manufacturers hold GMP and ISO certifications.

• Quality Assurance: Suppliers often provide Certificates of Analysis (CoA) and batch-specific documentation. Validation processes require rigorous testing for impurities, residual solvents, and potency.

Supply Chain Risks and Considerations

• Regulatory Restrictions: Restrictions on furazolidone can interrupt or limit supplies, especially where bans are in effect.

• Quality Variability: Variations in API quality exist between suppliers, necessitating quality audits and testing before procurement.

• International Trade Trends: Tariffs, trade restrictions, and geopolitical tensions influence sourcing options and pricing.

• Supply Security: Demand fluctuations influence production runs; most manufacturers operate on small to medium scales with flexible production capabilities.

Market Trends and Future Outlook

• The global furazolidone API market remains niche but stable due to its limited legal use in human medicine. The primary focus is on veterinary applications, where regulatory restrictions are less strict.

• Growing regulatory scrutiny in key markets is likely to reduce overall demand and constrain supply options.

• Alternative antimicrobial agents are replacing furazolidone in many applications, affecting API market stability.

Key Points Summary

• China dominates furazolidone API supply, with large-scale, GMP-certified manufacturers like Zhejiang Hailian Biotech and Jiangsu Guoxin Pharmaceutical.

• India contributes through companies such as Aurobindo Pharma and Hetero Labs, offering cost-effective options.

• Global regulatory restrictions impact supply, with bans in Western markets reducing demand and supply opportunities.

• Quality and certification are crucial in procurement, with GMP and ISO certificates preferred.

• Supply chain risks include regulatory changes, quality variability, and geopolitical tensions.

Key Takeaways

• The primary source of furazolidone API is Chinese manufacturers; Indian companies supply smaller volumes.

• Regulatory restrictions in major markets limit market size but sustain niche uses, mainly in veterinary medicine.

• Quality certifications significantly influence procurement decisions.

• Supply chain stability depends on geopolitical factors and evolving regulations.

• Alternative antimicrobials are reducing furazolidone's market share, affecting API manufacturing and sourcing strategies.

FAQs

1. Who are the main global producers of furazolidone API?
Chinese companies such as Zhejiang Hailian Biotech and Jiangsu Guoxin Pharmaceutical dominate supply, with Indian firms like Aurobindo Pharma and Hetero Labs providing supplementary sources.

2. How do regulatory restrictions affect API sourcing for furazolidone?
Regulatory bans in several countries restrict import and use, reducing global demand and creating supply limitations especially for markets with strict use policies.

3. What certifications are most important for procurement of furazolidone APIs?
GMP (Good Manufacturing Practice) and ISO 9001 certifications are most valued, indicating compliance with quality standards suitable for regulated markets.

4. Are there regional differences in furazolidone API availability?
Yes. China and India lead production; European and North American sources are limited due to regulatory restrictions and smaller manufacturing capacities.

5. What future trends could impact furazolidone API sourcing?
Increased regulatory restrictions, declining demand, and the emergence of alternative antimicrobials are likely to reduce supply options and influence procurement strategies.

---

References

[1] U.S. Food and Drug Administration. (2022). Drug bans and restrictions. FDA.gov.
[2] European Medicines Agency. (2021). Market authorizations and restrictions. EMA.europa.eu.
[3] Global Industry Analysts. (2020). API Market Report.
[4] Chinese Pharmacopoeia. (2020). Standards for APIs.
[5] Indian Pharmacopoeia Commission. (2021). API manufacturing guidelines.